Specialties

In clinical practice, patients with both type 2 diabetes and heart failure with preserved ejection fraction (HFpEF) often present with overlapping symptoms and complex care needs. The evolving landscape of cardiometabolic treatment has brought new attention to GLP‑1 HFpEF diabetes management, especially as recent evidence suggests that glucagon-like peptide‑1 receptor …

Managing type 2 diabetes in people with advanced chronic kidney disease (CKD) and end-stage kidney disease (ESKD) on dialysis presents unique clinical challenges. With the 2026 Standards of Care increasingly shifting the focus toward cardio-renal outcomes, many clinicians are asking: how far can we go safely with GLP‑1 receptor agonists …

Glucagon‑like peptide‑1 (GLP‑1) receptor agonists have revolutionized type 2 diabetes and obesity treatment—but could they also impact your brain? As headlines tout possible cognitive benefits, many patients and clinicians are asking: Can GLP‑1 drugs lower dementia risk? This article breaks down what we know so far, explains the science behind …

Living with diabetes can take a serious toll on a person’s mental well-being. Depression, anxiety, and other psychiatric conditions often go hand-in-hand with chronic illnesses, and diabetes is no exception. Yet, despite the deep connection between mental health and diabetes, care for these conditions remains siloed. This article gives clinicians …

Did you know that women with diabetes have a significantly higher risk of heart disease compared to men with diabetes? While many of the standard care guidelines apply to all patients, women often face additional, underrecognized threats to their heart and metabolic health. Understanding how sex-specific factors—such as hormonal changes, …

  As the burden of diabetic kidney disease (DKD) continues to grow, so does the urgency for early, evidence-based interventions. The concept of kidney protection diabetes is shifting—clinicians are now encouraged to initiate therapy before substantial kidney function loss occurs. Two major drug classes—SGLT2 inhibitors and GLP‑1 receptor agonists—are leading …

Managing diabetes in older adults isn’t just about adjusting medications—it’s about seeing the full picture of aging, frailty, and functionality. New 2025 standards highlight the need to assess frailty and functional status when setting A1C goals in elderly patients. But how do clinicians know when it’s time to de-intensify therapy …

The CKM framework in diabetes care—focusing on cardiovascular, kidney, and metabolic health—is more than a trend. It’s a clinical necessity. The ADA’s 2025 Standards of Care urge clinicians to manage these overlapping risks together, not separately. Why? Because patients with diabetes deserve outcomes that go beyond just A1C. This article …

When a child is diagnosed with diabetes, the clinical response extends beyond prescriptions and in-office education. Managing this chronic condition in school settings presents unique challenges and opportunities. For clinicians, understanding how to support diabetes management at school is essential—not only to safeguard the student’s health, but to empower families …

Diabetes distress and burnout are common but often overlooked challenges affecting people with diabetes. These emotional burdens can negatively influence self‑management, medication adherence, and glycemic control. In routine clinical visits, especially those limited to 15 minutes, clinicians may struggle to address emotional and psychological concerns alongside medical management. However, integrating …